Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
1.540
-0.900 (-36.89%)
At close: Sep 15, 2026, 4:00 PM EDT
1.460
-0.080 (-5.19%)
Pre-market: Sep 16, 2026, 8:48 AM EDT
Scinai Immunotherapeutics Revenue
Scinai Immunotherapeutics had revenue of $460.00K in the quarter ending June 30, 2026, with 145.99% growth. This brings the company's revenue in the last twelve months to $1.49M, up 29.64% year-over-year. In the year 2025, Scinai Immunotherapeutics had annual revenue of $1.31M with 99.24% growth.
Revenue (ttm)
$1.49M
Revenue Growth
+29.64%
P/S Ratio
0.59
Revenue / Employee
$33,044
Employees
45
Market Cap
877.83K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31M | 653.00K | 99.24% |
| Dec 31, 2024 | 658.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 27.82M |
| Decoy Therapeutics | 227.63K |
| Biodexa Pharmaceuticals | 104.90K |
| Endovia Health Sciences | 32.09K |
| Virax Biolabs Group | 12.42K |
| Valion Bio | -86.00K |
SCNI News
- 7 days ago - Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business - PRNewsWire
- 23 days ago - Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum - PRNewsWire
- 26 days ago - Scinai Immunotherapeutics Ltd – ADR trading halted, news pending - TheFly
- 5 weeks ago - Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration - PRNewsWire
- 3 months ago - Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - PRNewsWire
- 3 months ago - Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - PRNewsWire
- 4 months ago - Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - PRNewsWire
- 4 months ago - Why Is Scinai Immunotherapeutics Stock (SCNI) Up Today? - TipRanks